Results 61 to 70 of about 163,730 (308)
Application of Nanotechnology in Therapeutic Cancer Vaccines
Advanced NanoBiomed Research, 2023 Cancer vaccines stimulate the immune system within the body by introducing tumor antigens in various forms, such as tumor cells, tumor‐related proteins or peptides, and genes expressing tumor antigens, into the body.
Jianmei Guo +6 more
doaj +1 more source
Advances in Immunotherapy and Vaccine for Prostate Cancer
Annals of Urologic Oncology, 2023 Prostate cancer is one of the most common malignant tumors of the urinary system. The incidence of prostate cancer is high in the elderly male patients, which seriously threatens the life and health. In recent years, immunotherapy to activate anti-cancer
Wei Zhou, Yikai Zhang
doaj +1 more source
Development of Therapeutic Vaccines for Ovarian Cancer
, 2020 Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses.
Jonathan S. Berek +2 more
core +1 more source
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
, 2021 The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer types ...
Howard Donninger +3 more
core +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Advanced Materials, EarlyView.Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source
Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
Cell Reports, 2019 Summary: Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1-2∗02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s.
K. Rachael Parks +18 more
doaj +1 more source
Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects
Advanced Materials, EarlyView.Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley +1 more source
Nature CommunicationsSimian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal ...
Massimiliano Bissa +24 more
doaj +1 more source
Potential association factors for developing effective peptide-based cancer vaccines
Frontiers in Immunology, 2022 Peptide-based cancer vaccines have been shown to boost immune systems to kill tumor cells in cancer patients. However, designing an effective T cell epitope peptide-based cancer vaccine still remains a challenge and is a major hurdle for the application ...
Chongming Jiang +14 more
doaj +1 more source
Advances in Cancer Vaccines for Digestive System Cancers: A Systematic Analysis of Clinical Trials. [PDF]
Cancer Manag ResJianing Li,1 Peili Wang2 1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China; 2Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, People’s Republic of ChinaCorrespondence: Peili Wang, Email ...
Li J, Wang P, Wang P.
europepmc +3 more sources